Wells Fargo Downgrades Boston Scientific to Equal-Weight, Lowers Price Target to $55

Benzinga Newsdesk www.benzinga.com Negative 87.1%

Neg 87.1% Neu 0% Pos 0%

Wells Fargo analyst Larry Biegelsen downgrades Boston Scientific (NYSE:BSX) from Overweight to Equal-Weight and lowers the price target from $75 to $55.